Abstract-Mineralocorticoids have been implicated in the pathogenesis of diastolic heart failure. On the contrary, angiotensin (Ang)-(1-7) has emerged as a potential strategy for treatment of cardiac dysfunction induced by excessive mineralocorticoid receptor activation. A critical question about the cardioprotective effect of Ang-(1-7) in hypertensive models is its dependence on blood pressure (BP) reduction. Here, we addressed this question by investigating the mechanisms involved in Ang-(1-7) cardioprotection against mineralocorticoid receptor activation. Sprague-Dawley (SD) and transgenic (TG) rats that overexpress an Ang-(1-7) producing fusion protein (TG(A1-7)3292) were treated with deoxycorticosterone acetate (DOCA) for 6 weeks. After treatment, SD rats became hypertensive and developed ventricular hypertrophy. These parameters were attenuated in TG-DOCA. SD-DOCA rats developed diastolic dysfunction which was associated at the cellular level with reduced Ca 2+ transient. Oppositely, TG-DOCA myocytes presented enhanced Ca 2+ transient. Moreover, higher extracellular signal-regulated kinase phosphorylation, type 1 phosphatase, and protein kinase Cα levels were found in SD-DOCA cells. In vivo, pressor effects of DOCA can contribute to the diastolic dysfunction, raising the question of whether protection in TG was a consequence of reduced BP. To address this issue, BP in SD-DOCA was kept at TG-DOCA level by giving hydralazine or by reducing the DOCA amount given to rats (Low-DOCA). Under similar BP, diastolic dysfunction and molecular changes were still evident in DOCA-hydralazine and SD-low-DOCA, but not in TG-DOCA. In conclusion, Ang-(1-7) protective signaling against DOCA-induced diastolic dysfunction occurs independently of BP attenuation and is mediated by the activation of pathways involved in Ca 2+ handling, hypertrophy, and survival. 
C linical studies have linked aldosterone excess to the development and progression of several different cardiovascular disease processes. 1 In the heart, aldosterone binds both mineralocorticoid receptor (MR) and glucocorticoid receptor triggering the activation of different signaling pathways. 2, 3 Activation of MR has been implicated in the development of diastolic dysfunction, 4 and its conditional expression in the heart leads to arrhythmias. 5 Di et al 6 have shown that combined increases of systemic angiotensin II (Ang II) and cardiac MR signaling culminated in additive effects in the heart leading to pronounced left ventricular hypertrophy (LVH) and diastolic dysfunction. Conversely, Ang-(1-7), which is an active peptide of renin-angiotensin system, is known to protect the heart against deoxycorticosterone acetate (DOCA)-induced fibrosis in rats. 7 Similar beneficial effects were observed by Santiago et al 8 in a transgenic (TG(A1-7)3292) rat model with increased circulating levels of Ang-(1-7) subjected to DOCA-salt treatment. However, in this study, cardioprotection was accomplished in a background of reduced blood pressure (BP), raising the question of whether Ang-(1-7) beneficial effect was a consequence of attenuated BP. Here, we investigated this critical question using a combination of in vivo measurements of cardiac function and molecular biology to evaluate signaling pathways activated in TG rats with chronic increase in plasmatic Ang-(1-7) treated with DOCA.
Results
TG and Sprague-Dawley (SD) rats presented similar systolic BP before treatment ( Figure 1A ). However, there were some echocardiographic parameters in TG that differed from those in SD. TG rats presented reduced LV internal dimension (at diastole), cardiac output, stroke volume, end-diastolic and systolic LV volumes, when compared with SD (Table  S1 in the online-only Data Supplement). These changes are in keeping with the reduced body weight of TG rats when compared with SD (body weight 481.8±8.2 g, n=11 SD versus 380.5±5.7 g, n=10 TG; P<0.05). Despite the LV volume changes noted, TG and SD rats presented comparable ejection fraction. After 6 weeks, systolic BP was greater in DOCA rats when compared with SD ( Figure 1A ). The increased BP in SD-DOCA correlated with significant changes in echocardiographic parameters (Table S1 ), which included decreases in cardiac output and chamber diameter, and a marked increase in LV mass. Moreover, DOCA rats showed decreases in stroke, end-systolic, and end-diastolic volumes. Despite these changes, DOCA-rats presented enhanced ejection fraction. In addition, hearts from SD-DOCA presented global abnormalities in systolic function, as seen by the increase in radial strain rate ( Figure 1C ), as well as reduced early peak diastolic to peak atrial velocity (E/A) ratio ( Figure 1B) , which is an indicative of diastolic dysfunction. Thus, after 6 weeks SD-DOCA rats developed concentric LVH and diastolic dysfunction.
Two weeks after the beginning of DOCA treatment, TG rats became hypertensive and remained hypertensive until the end of treatment period ( Figure 1A) . Comparatively, the DOCA-induced rise in BP was significantly attenuated in TG rats versus SD, as previously described. 8 TG-DOCA rats presented significant increases in LV posterior wall and interventricular septal thickness, at systole, when compared with TG (Table S1 ). All remaining parameters were similar between TG and TG-DOCA. In general, most cardiac changes observed in SD-DOCA were prevented or attenuated in TG-DOCA. In addition, TG-DOCA rats did not show changes in E/A ratio or in radial strain rate ( Figure 1B and 1C) . Thus, echocardiography data clearly show that lifetime increase in plasmatic Ang-(1-7) prevents the progression of hypertensive disease to diastolic dysfunction in TG rats in response to MR activation.
We then investigated potential molecular pathways underlying Ang-(1-7) cardiac protection. To better correlate cellular data with in vivo findings, we used freshly isolated myocytes from LV. Figure 1D shows significant upregulation of hypertrophic markers, atrial natriuretic peptide and β-myosin heavy chain in SD-DOCA myocytes, an effect that was attenuated in LV myocytes from TG-DOCA. In addition, we assessed protein levels of angiotensin-converting enzyme (ACE) 2 and receptor Mas. In TG-DOCA cardiomyocytes, expression of ACE2, the main enzyme responsible for Ang-(1-7) synthesis in the heart, 9 is increased when compared with SD or TG ( Figure  S1A ). Yet, expression of Mas was found increased only in SD-DOCA myocytes ( Figure S1B Figure  S2C ). TG-DOCA SERCA2 levels were comparable with controls. SERCA activity is regulated by phospholamban, whereas dephosphorylated phospholamban inhibits SERCA, phosphorylation of phospholamban at Thr17 reverses this inhibition.
11 Figure S2D shows that SD-DOCA cells presented reduced phospholamban Thr17 phosphorylation. Opposite results were observed in TG-DOCA myocytes. The status of phospholamban phosphorylation is in part dependent on the activity of type 1 phosphatase (PP1). 12 Although PP1 levels were significantly increased in cardiomyocytes from SD-DOCA, its expression was reduced in TG-DOCA ( Figure S2E ). We next assessed protein kinase Cα (PKCα) levels. PKCα directly phosphorylates protein phosphatase inhibitor-1, thus increasing PP1 activity. 13 PKCα expression was elevated in SD-DOCA myocytes, a pattern that was not seen in TG-DOCA ( Figure S2F ). Figure S3A shows that extracellular signal-regulated kinase, a key modulator of hypertrophic programming, is more activated in cardiomyocytes from SD-DOCA. This finding is consistent with the ability of Ang-(1-7) to attenuate MR-induced hypertrophy. The serine/threonine kinase Akt is known as a regulator of myocyte survival. 14 Figure S3B shows that TG myocytes presented increased phosphorylation of Akt (pAkt), which remains activated in response to DOCA. Conversely, reduced pAkt was found in SD-DOCA myocytes. Altogether, these results demonstrate the profound cardiomyocyte remodeling that occurs in DOCA myocytes. Notably, this signaling profile is modulated in TG-DOCA, indicating that Ang-(1-7)-induced protection against diastolic dysfunction is mediated at the myocyte level, and occurs independently from moderately high BP levels found in TG-DOCA rats. These findings raised the critical question of whether Ang-(1-7) protective signaling was a result of attenuated BP observed in TG-DOCA versus SD-DOCA rats. To address this question, SD rats were subjected to 2 distinct protocols of DOCA treatment to maintain rats at similar BP. In the first protocol, rats received normal DOCA load and BP was kept at the TG-DOCA level by giving hydralazine, an antihypertensive agent 15 (DOCA-Hydra). In the second protocol, rats received reduced amount of DOCA (SD-low-DOCA) to control BP. Figure 2A shows that using either protocol we could efficiently maintain BP in SD-DOCA-Hydra and SD-low-DOCA rats to levels that were similar to TG-DOCA.
Our first set of analyses involved the comparison of echocardiography values obtained from SD rats submitted to each DOCA treatment (Table S2 ). Under conditions of moderately high BP (≈145 mmHg), both SD-DOCA-Hydra and SD-low-DOCA displayed significant alterations in echocardiography parameters when compared with SD rats. However, the magnitude of LV remodeling was greater in SD-DOCA-Hydra than in SD-low-DOCA rats, confirming a predominant effect of DOCA load in the cardiac alterations observed in this model. Overall, most cardiac parameters were similar between SD-DOCA-Hydra and SD-DOCA except for changes in cardiac output, stroke volume, and end-diastolic LV volume that were more pronounced in SD-DOCA. Nevertheless, despite variations in the magnitude of cardiac remodeling between experimental groups, all SD rats receiving DOCA exhibited diastolic dysfunction ( Figure 2B ).
Next, we compared echocardiography parameters between SD-DOCA-Hydra and TG-DOCA. Representative images are displayed in Figure 2C . Under conditions of similar BP, the increase in cardiac mass and ejection fraction were more pronounced in SD-DOCA-Hydra than in TG-DOCA. Moreover, significant alterations in chamber dimension, fractional shortening, and E/A ratio were seen only in SD-DOCA-Hydra (Table; Figure 2B ) supporting the notion that Ang-(1-7) beneficial effects against DOCA-induced remodeling occur independently from the attenuation in BP.
Next, we investigated the signaling pathways activated in BP-controlled DOCA rats. Under conditions of similar BP, enhanced Ca 2+ release was observed in cardiomyocytes from all groups subjected to DOCA treatment ( Figure 3A and 3B). Thus, in opposition to data obtained from SD-DOCA, DOCA-Hydra cardiomyocytes did not show reduced Ca 2+ levels. The enhanced Ca 2+ transient amplitude in DOCAHydra cardiomyocytes occurred in a context of reduced SERCA2 protein ( Figure 3C ) and increased phospholamban Thr17 levels ( Figure 3D ). Likewise, TG-DOCA myocytes presented increased phospholamban Thr17 phosphorylation, but normal SERCA levels. In addition, DOCA-Hydra cardiomyocytes showed increased PP1, PKCα ( Figure 3E and 3F), and phosphorylation of extracellular signal-regulated kinase ( Figure S4A ). DOCA-Hydra myocytes also presented increased pAkt when compared with SD ( Figure S4B ). Yet, TG-DOCA pAkt levels were even higher. These cellular data show that DOCA-Hydra rats, maintained under conditions of moderate hypertension, developed a cellular remodeling that resembles in many aspects the profile activated in severely hypertensive SD-DOCA rats.
Our next goal was to compare TG-DOCA with rats that received the half amount of DOCA to control BP. When SD-low-DOCA rats were compared with TG-DOCA, echocardiographic values were generally similar, except for a decrease in chamber dimension (at diastole) that was greater in TG-DOCA (Table) . Considering the fact that TG-DOCA rats received almost twice the amount of DOCA given to SD-low-DOCA, this finding once again is in line with our main hypothesis that Ang-(1-7) provides beneficial effects that are independent of its pressor effects. This hypothesis is furthermore reinforced by the observation that SD-low-DOCA rats present a decrease in E/A ratio ( Figure 2B ) and alterations in both longitudinal and radial parameters ( Figure S5A ; Table S3 ) that were not seen in TG-DOCA. Likewise, DOCA-Hydra rats presented global changes in contractility. Supporting this finding, upregulation of atrial natriuretic peptide and β-myosin heavy chain transcripts was observed only in LV cardiomyocytes from SD-DOCAHydra and SD-low-DOCA rats ( Figure S5B ).
Discussion
Here, we show that in vivo Ang-(1-7) protective signaling against DOCA-induced diastolic dysfunction occurs independently of its lowering BP effects and is mediated at the cardiomyocyte level by the activation of molecular pathways involved in Ca 2+ handling, hypertrophy, and cell survival. By dissociating the BP effect of Ang-(1-7), we were capable of showing that BP attenuation in TG-DOCA represents a minor component of Ang-(1-7) beneficial effects. In addition, we show that Ang-(1-7) protective signaling occurs even under conditions of moderately high BP because TG-DOCA rats were hypertensive. Altogether, these findings provide the mechanistic input necessary to develop new strategies for 16, 17 Preclinical data have shown strong evidence that Ang-(1-7) effectively prevents cardiac remodeling induced by DOCA-salt treatment, 7, 8 suggesting that Ang-(1-7) could be an important therapeutic strategy to reduce pathology associated to conditions of increased MR activation. In addition, previous study has linked the beneficial effects of MR blocker therapy to increased cardiac ACE2 activity 18 raising the possibility that increases in Ang-(1-7) formation could contribute to the beneficial effects of MR antagonism. Here, we also provide evidence that cardioprotective signaling against diastolic dysfunction correlates with enhanced ACE2, by showing the increase in ACE2 expression in TG-DOCA myocytes.
Diastolic dysfunction is a common entity in hypertensive patients. 10 In our model, activation of MR leads to hypertension that progress to concentric LVH and diastolic dysfunction in SD rats. When BP of SD-DOCA rats was maintained constant by the administration of hydralazine or by reducing the amount of DOCA, the magnitude of LVH was attenuated, but it was still significant. In addition, both diastolic dysfunction and abnormalities in global contractility were evident in hearts from DOCA-Hydra and SD-low-DOCA. Thus, we conclude that both BP level and DOCA load contribute to the magnitude of cardiac dysfunction induced by MR activation. This observation is consistent with a previous study showing that pharmacological control of BP is associated to a decrease in LV mass 19 and supported by clinical data showing that tighter control of systolic BP was associated with a reduction in development of LV hypertrophy. 20 However, it is clear that BP-independent actions of DOCA exert a prominent role during the development of diastolic dysfunction with lower degree of remodeling found in SD-low-DOCA when compared with DOCA-Hydra.
In TG rats, progression of hypertensive disease was slowed because the development of LVH was significantly attenuated and both diastolic dysfunction and global abnormalities in systolic function were prevented. The fact that these beneficial effects occurred independently of Ang-(1-7) effects on BP may indicate a mechanism of considerable clinical importance. For instance, it shows that even under moderately high BP conditions, Ang-(1-7) is capable of activating specific signaling pathways in cardiomyocytes that are involved in attenuation of LVH thus delaying the onset of diastolic dysfunction. The fact that LVH is an independent risk factor for the development of HF reinforces the importance of this finding. In addition, others 7, 8, 21 have demonstrated that Ang-(1-7) prevents extracellular matrix deposition, a key event in the transition from LVH to symptomatic HF that may also contribute to Ang-(1-7) protection in TG-DOCA.
Apart from hemodynamic factors, humoral factors, such as endothelin, and sympathetic activation also contribute to the cardiovascular remodeling observed in DOCA rats. 22 This knowledge further reinforces the idea that Ang-(1-7) exerts beneficial effects even under conditions that involve complex activation of different signaling pathways.
Santiago et al 8 have previously reported an increase in cardiac Ang-(1-7) levels in TG-DOCA rats, a finding that is further supported by our data showing enhanced ACE2 expression in TG-DOCA myocytes. The increase in cardiac ACE2/Ang-(1-7) provides the basis for direct local protective effects of Ang-(1-7) in cardiac cells from TG-DOCA, yet the mechanisms mediating this phenomenon remain unclear.
Our data suggest that in vivo Ang-(1-7) acts directly in ventricular cells modulating signaling pathways that are activated during the progression from hypertensive disease to diastolic dysfunction. At the cardiomyocyte level, the signaling profile activated in DOCA-Hydra rats is distinct from that seen in TG-DOCA. This knowledge implies that the attenuation of BP by Ang-(1-7) represents a minor component of Ang-(1-7) protective actions. Although antihypertensive effects of Ang-(1-7) have been previously reported, 23, 24 our findings contrast to studies showing a lack of effect of Ang-(1-7)/Mas receptor blockers on BP levels. 7, 25, 26 Further studies will be required to elucidate under what conditions Ang-(1-7) affects or does not affect BP.
Impaired Ca 2+ homeostasis is a key feature in the transition from compensatory hypertrophy to HF. 27 SD-DOCA myocytes present abnormal Ca 2+ handling caused, at least in part, by reduced SERCA2 activity. This reduction in SERCA2 activity reduces the speed of removal of Ca 2+ from the cytoplasm to the sarcoplasmic reticulum, thereby contributing to diastolic dysfunction. Likewise, SD-DOCA-Hydra myocytes presented reduced SERCA2. Yet, phospholamban phosphorylation at Thr17 and Ca 2+ transient amplitude were elevated in comparison with SD, indicating that the increase in phospholamban phosphorylation compensated for reduced SERCA2 in DOCA-Hydra myocytes. In hypertensive TG-DOCA rats, we observe the ability of Ang-(1-7) to prevent DOCA-induced SERCA2 downregulation. This is an important aspect of in vivo Ang-(1-7) signaling because other groups have demonstrated a critical role of SERCA in attenuating the transition to HF in pressure-overloaded mice. 28 It is worth mentioning the fact that increased phosphorylated phospholamban at Thr17 occurs in cardiomyocytes from SD-DOCA-Hydra rats, and its phosphorylation is maintained in TG-DOCA rats, indicating that DOCA-induced phosphorylation of phospholamban is preserved in conditions of increased Ang-(1-7) signaling. Likewise, we have previously demonstrated in vitro that aldosterone treatment of cardiomyocytes leads to an increase in phosphorylated phospholamban that is maintained in the presence of Ang- (1-7) . 29 Contrary to what is seen with phospholamban, most of the cellular changes induced by MR activation are antagonized by Ang- (1-7) . Accordingly, previous studies have shown the ability of Ang-(1-7) to antagonize the increase in extracellular signal-regulated kinase phosphorylation induced by Ang II. 30, 31 Another key feature of cardiomyocytes from TG-DOCA rats is the decrease in PP1 levels. PP1 expression is upregulated in failing hearts 32 and increases in its activity can account for reduced sarcoplasmic reticulum Ca 2+ uptake and therefore reduced ventricular function.
PKCα is known to phosphorylate titin, 33 the myofilament protein responsible for cardiomyocyte passive tension. Alteration in titin phosphorylation represents an important mechanism in the development of diastolic dysfunction.
Elevation of PKCα was observed in all SD-DOCA receiving rats, including SD-low-DOCA (data not shown), but it was absent in TG-DOCA, which may explain the improvement in diastolic dysfunction in this model. Consistent with these results, Mori et al 35 showed that Ang-(1-7) infusion prevented PKCα elevation in db/db mice.
Of all signaling pathways investigated, only Akt was activated in TG rats. The fact that Akt represents an important survival pathway 36 is consistent with the cardioprotective role of Ang-(1-7) . Supporting this assumption, we and others have previously shown that Ang-(1-7) leads to increased pAkt in the heart. 37, 38 Thus, Ang-(1-7) protective signaling against diastolic dysfunction occurs independently of its lowering BP effects and is mediated, at least in part, at the myocyte level by the activation of key signaling pathways.
Perspectives
Ang- (1-7) is a biologically active end product of the reninangiotensin system, with great potential for therapeutic use. The finding that Ang-(1-7), independently from its BP lowering effects, activates signaling pathways in cardiomyocytes that prevent the transition from LVH to diastolic dysfunction is potentially important because it provides the knowledge for the use of Ang-(1-7) alone or in combination with other drugs for the treatment of patients with cardiac disease. 
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DOCA-salt hypertension
Rats were anesthetized and unilaterally nephrectomized. Silicone rubber impregnated with DOCA (50 mg/kg/week; Sigma) was implanted subcutaneously, and rats were offered 0.5% saline/0.2% KCl to drink, during 6 weeks, as previously described by our group.
2 SD-DOCA-Hydra rats received the same amount of DOCA (50mg/kg/week) plus 10mg/kg/day hydralazine added to the drinking water. Control rats were also uninephrectomized but received a silicone rubber implant without DOCA and were offered tap water to drink. SD-Low-DOCA rats received 30mg/kg/ week during 6 weeks. Systolic arterial pressure (SAP) was evaluated by tail cuff plethysmography (RTBP2000, Kent Scientific), one day before the DOCA implant and every week during treatment.
Echocardiography
Analysis. Animals underwent transthoracic echocardiographic examination after 6 weeks of DOCA-Salt treatment. In vivo cardiac morphology and function were assessed noninvasively using a highfrequency, high-resolution echocardiographic system consisting of a VEVO 2100 ultrasound machine equipped with a 16-21MHz bifrequencial transducer (Visual Sonics, Toronto, Canada). The rats were anaesthetized with 5% isoflurane for induction, and placed in supine position on an imaging stage equipped with builtin electrocardiographic electrodes for continuous heart rate monitoring and a heater to maintain the body temperature at 37
• C. Anesthesia was sustained via a nose cone with 2.5% isoflurane. Ultrasound gel was applied to the anterior chest that was shaved after anesthesia induction and high-resolution images were obtained in the right and left parasternal long and short axes and apical orientations. Standard B-mode images of the heart and pulsed wave Doppler images of the mitral inflow were acquired. Left ventricular (LV) dimensions and wall thickness were measured at the level of the papillary muscles in left and right parasternal short axis during the end systole and end diastole. LV ejection fraction (EF) and fractional shortening (FS) were derived from chamber measurements. All measurements and calculations were done in accordance with the American Society of Echocardiography. The following M-mode measurements were performed: LV internal dimensions at diastole and systole (LVIDd and LVIDs), LV posterior wall dimensions at diastole and systole (LVPWd and LVPWs), and interventricular septal thickness at diastole and systole (IVSd and IVSs). Based on these parameters, end diastolic and end systolic LV volumes (EDLVV and ESLVV), FS, EF, stroke volume (SV), and cardiac output (CO) were calculated. Also, the radial strain from the bidimensional long axis view of the left ventricle was performed using the Vevostrain software. The following parameters were evaluated: velocity, displacement, strain, and strain rate.
Real Time PCR. Real time PCR was used as previously described to verify mRNA levels of ANP and β-MHC.
3
Freshly isolated ventricular myocytes and Ca 2+ recording Adult ventricular myocytes were freshly isolated and stored in DMEM media (Sigma), until they were used (within 1 h), as previously described. 
Western blot
Adult ventricular myocytes were harvested as described above and protein content was quantified according to Bradford protein assay. We used 40-60 µg of protein, and the samples were separated by SDS-PAGE. Antibodies and their sources are as follows: anti-SERCA2 (1:1000 ABR), anti-PKC alpha (1:1000, Millipore), anti-PP1 (1:1000, Santa Cruz), anti-phospho-ERK (1:1000, Cell Signaling), anti-ERK ( 1:1000, Cell Signaling), anti-PLN Thr 17 (1:1000 Santa Cruz), anti-phospho-AKT Ser 473 (1:1000, Cell Signaling), anti-AKT (1:1000, Cell signaling), anti-ACE2 (1:1000, Santa Cruz), anti-receptor Mas (1:1000, Alomone) and anti-GAPDH (1:3000, Santa Cruz). Protein expression levels were detected by chemiluminescence reaction (ECL plus, GE Healthcare) and the intensity of them was evaluated by densitometric analysis using ImageQuant LAS 4000 (GE Healthcare). Protein levels were normalized by using anti-GAPDH antibody.
Statistical Analyses. Data are presented as mean ± SEM. For comparisons of two variables we used Student's t test and for comparison of more than two variables we used One Way or Two Way ANOVA. The level of significance was set to values of p<0.05. 
